Overview

  • Product name

    Anti-ILF3/NF90 antibody [EPR3626] (HRP)
    See all ILF3/NF90 primary antibodies
  • Description

    Rabbit monoclonal [EPR3626] to ILF3/NF90 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: IHC-P, WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide within Human ILF3/NF90. The exact sequence is proprietary.

  • Positive control

    • WB: Raji, HeLa and K562 whole cell lysates. IHC-P: normal human kidney tissue sections
  • General notes

     This product was previously labelled as ILF3

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab206250 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/5000. Detects a band of approximately 95,110 kDa (predicted molecular weight: 95 kDa).

Target

  • Function

    May facilitate double-stranded RNA-regulated gene expression at the level of post-transcription. Can act as a translation inhibitory protein which binds to coding sequences of acid beta-glucosidase (GCase) and other mRNAs and functions at the initiation phase of GCase mRNA translation, probably by inhibiting its binding to polysomes. Can regulate protein arginine N-methyltransferase 1 activity. May regulate transcription of the IL2 gene during T-cell activation. Can promote the formation of stable DNA-dependent protein kinase holoenzyme complexes on DNA.
  • Tissue specificity

    Ubiquitous.
  • Sequence similarities

    Contains 2 DRBM (double-stranded RNA-binding) domains.
    Contains 1 DZF domain.
  • Post-translational
    modifications

    Phosphorylated by RNA-dependent protein kinase (EIF2AK2).
    Methylated by protein arginine N-methyltransferase 1.
    Arg-609 is dimethylated, probably to asymmetric dimethylarginine.
  • Cellular localization

    Nucleus > nucleolus. Cytoplasm. Localized in cytoplasmic mRNP granules containing untranslated mRNAs.
  • Information by UniProt
  • Database links

  • Alternative names

    • CBTF antibody
    • Double stranded RNA binding protein 76 antibody
    • Double-stranded RNA-binding protein 76 antibody
    • DRBF antibody
    • DRBP76 antibody
    • ILF3 antibody
    • ILF3_HUMAN antibody
    • Interleukin enhancer binding factor 3 antibody
    • Interleukin enhancer-binding factor 3 antibody
    • M phase phosphoprotein 4 antibody
    • M-phase phosphoprotein 4 antibody
    • MPHOSPH4 antibody
    • MPP4 antibody
    • NF AT 90 antibody
    • NF-AT-90 antibody
    • NF110 antibody
    • NF90 antibody
    • NFAR antibody
    • Nuclear factor associated with dsRNA antibody
    • Nuclear factor of activated T cells 90 kDa antibody
    • Nuclear factor of activated T-cells 90 kDa antibody
    • TCP80 antibody
    • Translational control protein 80 antibody
    see all

Images

  • IHC image of ILF3/NF90 staining in a section of formalin-fixed paraffin-embedded normal human kidney*, performed on a Leica BOND™. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab206250, 1/500 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

  • All lanes : Anti-ILF3/NF90 antibody [EPR3626] (HRP) (ab206250) at 1/5000 dilution

    Lane 1 : Raji (Human Burkitt's lymphoma cell line) Whole Cell Lysate
    Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 3 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 95 kDa
    Observed band size: 110,95 kDa
    why is the actual band size different from the predicted?


    Exposure time: 30 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab206250 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab206250 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab206250.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up